President and CEO of Adma Biologics Inc (30-Year Financial, Insider Trades) Adam S Grossman (insider trades) bought 85,714 shares of ADMA on 02/11/2020 at an average price of $3.5 a share. The total cost of this purchase was $299,999.
ADMA Biologics Inc is a biopharmaceutical company. The company develops and manufactures specialty plasma-based biologics for the proposed treatment of immune deficiencies and prevention of certain infectious diseases. ADMA Biologics Inc has a market cap of $211.180 million; its shares were traded at around $3.56 with and P/S ratio of 8.67. ADMA Biologics Inc had annual average EBITDA growth of 8.50% over the past five years. GuruFocus has detected 2 severe warning signs with ADMA Biologics Inc. .
CEO Recent Trades:
- President and CEO Adam S Grossman bought 85,714 shares of ADMA stock on 02/11/2020 at the average price of $3.5. The price of the stock has increased by 1.71% since.
CFO Recent Trades:
- EVP, CFO Brian Lenz bought 7,142 shares of ADMA stock on 02/11/2020 at the average price of $3.5. The price of the stock has increased by 1.71% since.
Directors and Officers Recent Trades:
- 10% Owner Life Sciences Maste Perceptive bought 4,563,700 shares of ADMA stock on 02/11/2020 at the average price of $3.5. The price of the stock has increased by 1.71% since.
- Director Lawrence P. Guiheen bought 20,000 shares of ADMA stock on 02/11/2020 at the average price of $3.5. The price of the stock has increased by 1.71% since.
- CSO and CMO James Mond bought 4,285 shares of ADMA stock on 02/11/2020 at the average price of $3.5. The price of the stock has increased by 1.71% since.
- Director Jerrold B Grossman bought 45,714 shares of ADMA stock on 02/11/2020 at the average price of $3.5. The price of the stock has increased by 1.71% since.
For the complete insider trading history of ADMA, click here
.
